EP Patent

EP2120568A4 — FIXED PHARMACOLOGICAL REPORTS IN THE TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISEASES

Assigned to Jazz Pharmaceuticals Therapeutics Inc · Expires 2010-04-21 · 16y expired

What this patent protects

Patent listed against Cytarabine.

Drugs covered by this patent

Cytarabine (Cytarabine) · Nippon Shinyaku Co., Ltd.

Patent Metadata

Patent number: EP2120568A4
Jurisdiction: EP
Classification: —
Expires: 2010-04-21
Drug substance claim: No
Drug product claim: No
Assignee: Jazz Pharmaceuticals Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.